Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
US11286486B2 · kind B2 · utility
4Cited by
14References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 1, 2020 |
| Grant date | Mar 29, 2022 |
| Priority date | — |
| Expiry date | May 1, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.